OCUL Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Ocular Therapeutix Inc (OCUL) is not a strong buy at the moment for a beginner investor with a long-term strategy. Despite bullish analyst ratings and hedge fund interest, the technical indicators suggest a bearish trend, and the financial performance shows declining revenue and negative net income. The options data also indicates a bearish sentiment in the short term. The stock may not align with the investor's preference for long-term growth opportunities.
The MACD is slightly positive at 0.0141, indicating weak bullish momentum, but the RSI at 39.808 is neutral. Moving averages are bearish (SMA_200 > SMA_20 > SMA_5), and the stock is trading near its pivot level of 9.147. Support levels are at 8.49 and 8.084, while resistance levels are at 9.804 and 10.21. Overall, the technical indicators suggest a bearish trend.
Analysts are bullish, with BofA and H.C. Wainwright raising price targets to $21, citing confidence in Axpaxli's development and upcoming trial results.
Hedge funds are significantly increasing their positions, with a 2312.47% increase in buying activity over the last quarter.
The company's financials show a -22.43% YoY revenue decline and negative net income, despite slight improvements in EPS and net income.
No recent news or significant insider trading trends.
Technical indicators and options data suggest a bearish short-term outlook.
In Q4 2025, revenue dropped by -22.43% YoY to $13.25M. Net income improved by 33.62% YoY but remains negative at -$64.65M. EPS improved by 31.03% YoY to -0.38, and gross margin decreased by -5.39% YoY to 87.8%. Overall, the financials indicate weak growth trends.
Analysts are bullish, with recent upgrades in price targets from BofA ($21 from $18) and H.C. Wainwright ($21 from $19). LifeSci Capital initiated coverage with an Outperform rating and a $55 price target, reflecting optimism about the company's pipeline and growth potential.
